Physician
Spcsa PLLC
Spcsa PLLC was paid $724K by Medicaid between Dec 2018 and Dec 2024, across 25 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 69% of everything it billed.
33Billing provider infoSPCSA PLLC
SAN ANTONIO, TX 78251
SAN ANTONIO, TX 78251
33aNPI1720008527assigned 07/21/2006
33bProvider typePain Medicine (Physical Medicine & Rehabilitation) Physician
28Total paid$724K
24GClaims21,726
24DCodes billed25
24AFirst – last monthDec 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Physical Medicine & Rehabilitation) Physician providers in Texas
Rank by total paid#2 of 24
Median peer was paid$6K
This provider vs. median123×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 76 | $210.13 | |
| 2019 | 1,105 | $7K | |
| 2020 | 2,066 | $43K | |
| 2021 | 6,014 | $219K | |
| 2022 | 5,339 | $190K | |
| 2023 | 3,950 | $157K | |
| 2024incomplete | 3,176 | $109K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 69% | 13,753 | 12,523 | $497K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 23% | 4,225 | 4,071 | $164K |
| 64483 | 2.6% | 88 | 86 | $19K | |
| 01936 | 2.4% | 187 | 133 | $17K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.7% | 226 | 176 | $13K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 384 | 372 | $6K |
| 01938 | <1% | 39 | 39 | $4K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 17 | 12 | $2K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 137 | 134 | $757.17 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 127 | 124 | $434.23 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 138 | 84 | $338.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 628 | 532 | $194.14 |
13 more codes
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 27 | $163.41 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 59 | $134.75 |
| 99152 | <1% | 14 | $115.47 | |
| 96132 | <1% | 26 | $84.30 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 612 | $32.22 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 297 | $16.40 |
| J2704 | Injection, propofol, 10 mg | <1% | 461 | $0.43 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 59 | $0.00 |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | 0% | 25 | $0.00 |
| 99072 | 0% | 133 | $0.00 | |
| 96130 | 0% | 26 | $0.00 | |
| 96138 | 0% | 26 | $0.00 | |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALVARADO, SERGIO (AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Sergio A. Alvarado, M.D., P.A. | El Paso, TX | $9K |
| Sports Medicine and Bone of El Paso, PA | El Paso, TX | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.